ANNVILLE, Pa.--(BUSINESS WIRE)--L2P Research Labs, a leading preclinical CRO, today announced its annual research accomplishments.
Dr. Suresh Anaganti, Chief Executive Officer of L2P Research Labs, shared contribution to preclinical data published in Cell Reports.
Link: https://www.cell.com/cell-reports/pdf/S2211-1247(21)01308-5.pdf
In addition to prestigious Cell Reports, L2P also announces its contribution to research work published in Sciences advances.
Link: https://www.science.org/doi/epdf/10.1126/sciadv.abi7511
As a Contract Research Laboratory specialized in Immune oncology, we are happy to share that our Renal carcinoma tumor model has been used to study Alphataxin, a small molecule drug that elevates tumor infiltration of CD4+ T- cells.
Link: https://www.frontiersin.org/articles/10.3389/fonc.2021.739080/full
L2P Research Labs brings unique capabilities and solid reputation in providing Preclinical Research services. Recently, L2P added 5,000 SFT GLP-compliant testing facility in Long Island, focused on providing Bioanalytical services.
About L2P Research Labs
L2P Research is a Pennsylvania based Research organization that provides integrated R&D support in all the key areas of pharmaceutical development. With a large worldwide customer base, L2P provides a complete array of research services as required for Investigational New Drug Applications (IND).
